(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
3 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 5.92%
2.96% $ 15.67
@ $17.41
Emitido: 14 feb 2024 @ 14:15
Retorno: -9.99%
Señal anterior: feb 14 - 13:13
Señal anterior:
Retorno: 1.58 %
Live Chart Being Loaded With Signals
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens...
Stats | |
---|---|
Volumen de hoy | 604 700 |
Volumen promedio | 1.49M |
Capitalización de mercado | 972.00M |
EPS | $0 ( 2024-03-20 ) |
Próxima fecha de ganancias | ( $-0.640 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 19.35 |
ATR14 | $0.0180 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Peters Jeffrey Stuart | Sell | 42 500 | Employee stock option (right to buy) |
2024-04-04 | Peters Jeffrey Stuart | Buy | 42 500 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 42 500 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 147 | Common Stock |
2024-04-04 | Peters Jeffrey Stuart | Sell | 232 | Common Stock |
INSIDER POWER |
---|
43.87 |
Last 100 transactions |
Buy: 2 053 694 | Sell: 721 474 |
Volumen Correlación
MacroGenics Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
BNIXU | 0.951 |
AVIR | 0.933 |
CGEM | 0.914 |
EWTX | 0.907 |
SRPT | 0.9 |
FSEA | 0.899 |
VSTM | 0.894 |
ROVR | 0.894 |
HCCI | 0.893 |
NPCE | 0.892 |
10 Correlaciones Más Negativas | |
---|---|
CSSEN | -0.908 |
VNET | -0.901 |
KBNT | -0.899 |
CRCT | -0.894 |
KSPN | -0.89 |
AHPI | -0.888 |
VRM | -0.885 |
LHDX | -0.884 |
BSMO | -0.882 |
AXDX | -0.881 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
MacroGenics Inc Correlación - Moneda/Commodity
MacroGenics Inc Finanzas
Annual | 2023 |
Ingresos: | $58.75M |
Beneficio Bruto: | $58.13M (98.95 %) |
EPS: | $-0.000100 |
FY | 2023 |
Ingresos: | $58.75M |
Beneficio Bruto: | $58.13M (98.95 %) |
EPS: | $-0.000100 |
FY | 2022 |
Ingresos: | $151.94M |
Beneficio Bruto: | $144.56M (95.14 %) |
EPS: | $-1.950 |
FY | 2021 |
Ingresos: | $75.64M |
Beneficio Bruto: | $72.99M (96.50 %) |
EPS: | $-3.30 |
Financial Reports:
No articles found.
MacroGenics Inc
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico